CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, and muscle, today announced preliminary results from the ACE-031 Phase 1 single dose clinical trial indicating that ACE-031 was safe and well-tolerated at all dose levels and increased lean body mass. The results from this randomized, placebo-controlled study will be presented at the 14th International Congress of the World Muscle Society taking place in Geneva, Switzerland, September 9-12, 2009. In addition, Acceleron announced that it has initiated a multiple dose Phase 1 clinical trial for ACE-031.
